ERBB2 and cancer: Other examples of anti-HER2 ADCs whose antiproliferative activity is being evaluated in clinical trials for the treatment of HER2+ cancers are ARX788, TAK-522, A116, Tmab Duocarmizine, ALT-P7, DHE50815A, MEDI4276, and Tmab Deruxtecan [89,99,102,103,104,105].